BTN3A1 and prostate adenocarcinoma: In contrast, BTN3A1 expression was significantly lower in breast cancer (BRCA), kidney chromophobe (KICH), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), prostate adenocarcinoma (PRAD), and uterine corpus endometrial carcinoma (UCEC), in comparison with that in counterpart normal tissue controls (Fig. 1A).